Anti-Human IgG4 (Clone HP6025) – Purified No Carrier Protein

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

Clone HP6025 activity is directed against human IgG4.

IgG functions in the humoral immune response¹. There are four subclasses of IgG, and they are numbered according to decreasing abundance as IgG1 through IgG4. While IgG4 is the least abundant of these subclasses, it is the predominant IgG involved in chronic or repeated antigen exposure, leading to an anti-inflammatory response. IgG4 is not usually part of the antibody response to bacterial or viral infection. Rather, it dominates the response to allergens and parasitic worm infections.

IgG4 has unique properties relative to other IgG antibodies¹. IgG4 affinity for Fc receptors and complement is relatively lower and IgG4 is largely unable to activate antibody-dependent- immune effector responses. IgG4 also performs Fab-arm exchange and is more highly glycosylated. Additionally, the IgG4 response is blocking in nature and able to induce tolerance and limit inflammation in the host, and particularly protects against allergic inflammation.

IgG4 is produced by B cells that undergo class-switch recombination from IgM to IgG4 via T helper 2 cell responses¹.

IgG4 is produced by B cells and is present in serum.

Antigens

1 Rispens T, Huijbers MG. Nat Rev Immunol. 23(11):763-778. 2023.
2 Jefferis R, Reimer CB, Skvaril F, et al. Immunol Lett. 10(3-4):223-252. 1985.
3 Yamashita K, Haga H, Mikami Y, et al. Histopathology. 52(3):404-409. 2008.
4 Yamashita K, Haga H, Kobashi Y, et al. Am J Surg Pathol. 32(11):1620-1626. 2008.
5 Miyagawa-Hayashino A, Matsumura Y, Kawakami F, et al. Hum Pathol. 40(9):1269-1277. 2009.
6 Derakhshandeh R, Dimopoulos YP, Goodglick TA, et al. Balkan Med J. 38(4):239-243. 2021.